Introduction {#s1}
============

It was predicted that lung cancer would be diagnosed in over 215,000 individuals in the United States alone in 2008 [@pone.0012402-Jemal1]. Patients with locally advanced stage IIIA and IIIB (dry) disease who are not candidates for surgery are treated with definitive radiation therapy or combination chemoradiation therapy [@pone.0012402-Spira1]. Unfortunately even with treatment, the overall 5-year survival rate for NSCLC patients is only 10--15% [@pone.0012402-Greenlee1].

One of the challenges in lung cancer treatment with radiotherapy is the development of severe dose-limiting side effects. Esophagitis and pneumonitis are common acute radiation-induced normal tissue toxicities occurring in patients within one year following treatment. Presence of these toxicities can also cause a reduction in quality of life and may lead to chronic complications including lung fibrosis [@pone.0012402-Rubin1]. Currently, there are few predictors for the development of these toxicities based on clinical and dosimetric parameters [@pone.0012402-Robnett1]--[@pone.0012402-Wang1]. Therefore, the identification of additional reliable markers could help to tailor radiation regimens in order to administer the optimal therapeutic dose while minimizing toxicity.

Inflammation is a physiological response to cellular and tissue damage, including radiation-induced damage. Appropriate response to this damage is tightly regulated through a balance between proinflammatory and anti-inflammatory cytokines and signaling molecules [@pone.0012402-Dinarello1], [@pone.0012402-Opal1]. Genetic variation in key inflammation-related genes may cause a shift in balance resulting in deregulation of the inflammatory response and corresponding modulation of susceptibility to radiation-induced normal tissue damage [@pone.0012402-Barnett1]. Previous studies have investigated genetic variation in transforming growth factor-beta 1 (TGF-β1). This important cytokine is up regulated following radiation exposure and common variants located in *TGFB1* have been found to be associated with late normal tissue complications [@pone.0012402-Andreassen1]--[@pone.0012402-Quarmby1].

In this study, we utilized a pathway-based approach to analyze genetic variation from 59 SNPs in 37 inflammation-related genes with regard to risk of developing either acute esophagitis or pneumonitis following radiation therapy. We explored the main effects of single SNPs and also the cumulative effect of genetic variation within the inflammation pathway on toxicity risk. These results indicate that an individual\'s risk of developing these severe side effects may be modulated by germline variation in inflammation genes and may help to personalize radiation therapy for NSCLC.

Results {#s2}
=======

Patient Characteristics {#s2a}
-----------------------

A total of 173 non-Hispanic Caucasian patients with stage IIIA (n = 70 or 40.5%) or IIIB (dry) (n = 103 or 59.5%) were included in the analysis ([**Table 1**](#pone-0012402-t001){ref-type="table"}). Of these patients, 91 (52.6%) were men and 82 (47.4%) were women with a median age of 63.6 years. Most of the patients had a history of smoking with 46.8% (n = 81) being former smokers and 46.2% (n = 80) currently smoking or having quit within a year prior to diagnosis. Sixty-three (36.4%) of the tumors were classified as squamous cell carcinoma, 59 (34.1%) as adenocarcinoma, and 40 (23.1%) as non-small cell carcinoma, with the remainder (11 or 6.4%) as other NSCLC. Twenty-two patients were given a pre-treatment ECOG performance score ≥2. Nearly 80% (n = 138) of the patients received combination chemoradiation therapy, primarily with cisplatin or carboplatin (n = 142). A majority were treated with 3D radiotherapy (n = 72 or 41.6%). There were 78 occurrences of grade ≥2 esophagitis and 43 of grade ≥2 pneumonitis in our population. Twenty-three of these patients had both esophagitis and pneumonitis, while 75 patients had neither.
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###### Patient characteristics.

![](pone.0012402.t001){#pone-0012402-t001-1}

                                                 Esophagitis    Pneumonitis                                                
  ------------------------------ -------------- -------------- -------------- -------------- -------------- -------------- -----------
  **Gender**                                                                                                               
  Male                                 91         50(52.63)      41(52.56)                     73(56.15)      18(41.86)    
  Female                               82         45(47.37)      37(47.44)        0.993        57(43.85)      25(58.14)       0.104
  Total                               173             95             78                           130             43       
  **Age, mean(SD)**               63.60(9.98)    64.85(10.14)   62.08(9.64)       0.069       64.18(10.02)   61.86(9.78)      0.188
  **Smoking status**                                                                                                       
  Never                                12          6(6.32)        6(7.69)                       8(6.15)        4(9.30)     
  Former                               81         47(49.47)      34(43.59)                     53(40.77)      28(65.12)    
  Current & Recent Quitter             80         42(44.21)      38(48.72)        0.733        69(53.08)      11(25.58)     **0.007**
  Total                               173             95             78                           130             43       
  **Packyr, mean(SD)**            51.62(28.67)   53.67(28.37)   49.08(29.04)      0.315       53.71(29.41)   45.07(25.48)     0.102
  **Histology**                                                                                                            
  Adenocarcinoma                       59         26(27.37)      33(42.31)                     42(32.31)      17(39.53)    
  Squamous Cell Carcinoma              63         41(43.16)      22(28.21)                     48(36.92)      15(34.88)    
  Non-small Cell Carcinoma             40         21(22.11)      19(24.36)                     33(25.38)       7(16.28)    
  Other NSCLC                          11          7(7.37)        4(5.13)         0.118         7(5.38)        4(9.30)        0.481
  Total                               173             95             78                           130             43       
  **Clinical stage**                                                                                                       
  Stage IIIA                           70         41(43.16)      29(37.18)                     46(35.38)      24(55.81)    
  Stage IIB(dry)                      103         54(56.84)      49(62.82)        0.425        84(64.62)      19(44.19)     **0.018**
  Total                               173             95             78                           130             43       
  **Performance status**                                                                                                   
  0                                    52         23(24.21)      29(37.18)                     38(29.23)      14(32.56)    
  1                                    99         59(62.11)      40(51.28)                     75(57.69)      24(55.81)    
  2--4                                 22         13(13.68)       9(11.54)        0.180        17(13.08)       5(11.63)       0.908
  Total                               173             95             78                           130             43       
  **Treatment**                                                                                                            
  Radiation                            35         31(32.63)       4(5.13)                      29(22.31)       6(13.95)    
  Chemoradiation                      138         64(67.37)      74(94.87)     **\<0.0001**    101(77.69)     37(86.05)       0.237
  Total                               173             95             78                           130             43       
  **Radiation type**                                                                                                       
  2D                                   55         36(37.89)      19(24.36)                     47(36.15)       8(18.60)    
  3D                                   72         29(30.53)      43(55.13)                     46(35.38)      26(60.47)    
  IMRT                                 46         30(31.58)      16(20.51)      **0.005**      37(28.46)       9(20.93)     **0.013**
  Total                               173             95             78                           130             43       
  **Radiation dose, mean(SD)**    62.34(10.40)   60.75(12.64)   64.27(6.29)     **0.026**     61.68(11.63)   64.32(4.66)      0.149

There were no significant differences between patients who developed severe esophagitis and those who did not with regard to age, gender, smoking status, histology, clinical stage and performance status. However, patients who developed esophagitis were more likely to receive chemoradiation instead of radiation alone (*P*\<0.001), and more likely to receive a higher mean radiation dose (*P* = 0.026) compared to those who did not develop esophagitis. Interestingly, severe pneumonitis was more frequent in patients who were former smokers compared to current smokers or recent quitters (*P* = 0.007). Patients with stage IIIA patients were also more likely to develop pneumonitis (*P* = 0.018). For both esophagitis and pneumonitis, there was a significant difference in the occurrence of toxicity by the type of radiation therapy administered (*P* = 0.005 and 0.013, respectively).

Inflammation-related SNPs and Risk of Esophagitis {#s2b}
-------------------------------------------------

Among the 59 SNPs studied, a total of nine inflammation-related SNPs were found to be significantly associated with risk of esophagitis following radiation treatment ([**Table 2**](#pone-0012402-t002){ref-type="table"}). All of these variants remained significant at an FDR level of 10%. In addition, because esophagitis typically presents 4--6 weeks following initiation of radiation therapy, we also analyzed the effect of these variants using logistic regression. The results are similar to those from the Cox regression analysis (data not shown).
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###### Inflammation-related SNPs and risk of esophagitis.

![](pone.0012402.t002){#pone-0012402-t002-2}

                                                                         Grade \<2 n(%)   Grade ≥2 n(%)   [\*](#nt101){ref-type="table-fn"}HR        95% CI         *P* value    Q value                           Grade \<2 n(%)   Grade ≥2 n(%)   [\*](#nt101){ref-type="table-fn"}HR        95% CI         *P* value    Q value
  --------------------------------------------------------------------- ---------------- --------------- ------------------------------------- ------------------- ----------- ----------- ---------------------- ---------------- --------------- ------------------------------------- ------------------- ----------- -----------
  ***Proinflammatory cytokines, receptors, and related molecules***                                                                                                                                                                                                                                                      
  **IL6:rs1800795**                                                            94              76                                                                                            **PTGS2:rs20417**           94              76                                                                              
  CC                                                                        32(34.0)        30(39.5)                     1.00                                                                        GG               82(87.2)        54(71.1)                     1.00                                                  
  CG                                                                        53(56.4)        27(35.5)                     0.67                     0.38 to 1.18        0.162                          GC             **12(12.8)**    **20(26.3)**                 **1.90**                 **1.07 to 3.39**    **0.029**  
  GG                                                                         9(9.6)         19(25.0)                     1.70                     0.87 to 3.35        0.123                          CC                0(0.0)          2(2.6)                                                                            
  CC+CG vs. GG                                                               **85**          **57**                    **2.16**                 **1.18 to 3.94**    **0.013**   **0.052**          GC+CC               **12**          **22**                    **1.93**                 **1.10 to 3.39**    **0.029**   **0.052**
  **IL16:rs11556218**                                                          96              75                                                                                             **PTGS2:rs5275**           92              75                                                                              
  TT                                                                        58(60.4)        41(54.7)                     1.00                                                                        TT               51(55.4)        32(42.7)                     1.00                                                  
  TG                                                                        32(33.3)        22(29.3)                     0.86                     0.49 to 1.53        0.615                          TC               39(42.4)        33(44.0)                     1.43                     0.85 to 2.39        0.178    
  GG                                                                       **6(6.3)**     **12(16.0)**                 **2.14**                 **1.05 to 4.36**    **0.035**                        CC              **2(2.2)**     **10(13.3)**                 **2.71**                 **1.25 to 5.88**    **0.011**  
  TT+TG vs. GG                                                               **90**          **63**                    **2.28**                 **1.16 to 4.47**    **0.017**   **0.052**      *P* for trend                                                     **1.58**                 **1.09 to 2.27**    **0.014**   **0.052**
  **TNF:rs1799724**                                                            92              71                                                                                            **PTGS2:rs689470**          96              74                                                                              
  CC                                                                        74(80.4)        50(70.4)                     1.00                                                                        CC               92(72.3)        70(94.6)                     1.00                                                  
  CT                                                                      **12(13.0)**    **20(28.2)**                 **2.13**                 **1.17 to 3.86**    **0.013**                        CT                4(4.2)          3(4.1)                      2.67                     0.73 to 9.96        0.136     **0.072**
  TT                                                                         6(6.5)          1(1.4)                      0.91                     0.12 to 6.99        0.928                          TT                0(0.0)          1(1.4)                                                                            
  CT+TT                                                                      **18**          **21**                    **1.97**                 **1.10 to 3.50**    **0.022**   **0.052**          CT+TT               **4**            **4**                    **3.38**                 **1.09 to 10.49**   **0.035**  
  ***Anti-inflammatory cytokines, receptors, and related molecules***                                                                                                                                                                                                                                                    
  **IL4R:rs1801275**                                                           94              75                                                                                           **IL10RA:rs3135932**         95              76                                                                              
  AA                                                                        60(63.8)        40(53.3)                     1.00                                                                        AA               68(71.6)        43(56.6)                     1.00                                                  
  AG                                                                        34(36.2)        28(37.3)                     0.99                     0.58 to 1.68        0.973                          AG               24(25.3)        28(36.8)                     1.38                     0.83 to 2.28        0.217    
  GG                                                                         0(0.0)          7(9.3)                                                                                                  GG                3(3.2)          5(6.6)                      2.60                     0.99 to 9.83        0.053    
  AA+AG vs. GG                                                               **94**          **68**                    **4.12**                 **1.60 to 10.59**   **0.003**   **0.052**      *P* for trend                                                     **1.49**                 **1.01 to 2.20**    **0.046**   **0.083**
  **IL10:rs1800872**                                                           94              75                                                                                                                                                                                                                        
  CC                                                                        65(69.1)        43(57.3)                     1.00                                                                                                                                                                                            
  CA                                                                        27(28.7)        26(34.7)                     1.59                     0.93 to 2.72        0.093                                                                                                                                              
  AA                                                                       **2(2.1)**      **6(8.0)**                  **2.88**                 **1.15 to 7.22**    **0.024**                                                                                                                                            
  *P* for trend                                                                                                        **1.65**                 **1.11 to 2.45**    **0.013**   **0.052**                                                                                                                                

\*adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen, radiation type, and radiation dosage.

### Proinflammatory Genes {#s2b1}

Of these nine SNPs, six were among genes involved in the proinflammatory response: *IL6*, *IL16*, *TNF*, and *PTGS2* (COX2). Interleukin 6 (IL6):rs1800795 resulted in an 2.16-fold increased risk (95% CI:1.18--3.94) under the recessive model. A similar effect was observed for IL16:rs11556218 (HR:2.28, 95% CI:1.16--4.47). Patients with at least one tumor necrosis factor-α (TNF) variant rs1799724 had a nearly 2-fold increased risk (HR:1.97, 95% CI:1.10--3.50). Three SNPs in *PTGS2* modulated esophagitis risk in our patient population: rs20417, rs5275, and rs689470. PTGS2:rs5275 was associated with an increased risk (*P* for trend  = 0.014). For rs20417 and rs689470, carriers of at least one variant allele were at an increased risk (HR:1.93, 95% CI:1.10--3.39 and HR:3.38, 95% CI:1.09--10.49, respectively).

### Anti-inflammatory Genes {#s2b2}

SNPs in the IL4 receptor, IL10, and the alpha subunit of the IL10 receptor were found to be significantly associated with increased esophagitis risk. The IL10:rs1800872 and IL10RA:rs3135932 variants were both associated with significantly increased risks under the additive model with HRs of 1.65 (95% CI: 1.11--2.45) and 1.49 (95% CI: 1.01--2.20), respectively. IL4R:rs1801275 resulted in over a 4-fold increased risk (HR:4.12, 95% CI:1.60--10.59).

### Joint Analysis of Esophagitis Risk Alleles {#s2b3}

To understand the cumulative effect of unfavorable genotypes on risk of esophagitis, we performed a combined analysis. We included all significant SNPs identified from our individual SNP analysis and an additional seven SNPs reaching borderline significance at p\<0.10 ([**Table 3**](#pone-0012402-t003){ref-type="table"}). Patients with four unfavorable genotypes had a 3.71-fold increased risk (95% CI:1.53--8.99) compared to those with 0∼3 unfavorable genotypes. This risk increased to 8.85 (95% CI:4.19--18.68) for patients with five or more unfavorable genotypes. Furthermore, patients with an increasing number of unfavorable genotypes developed esophagitis significantly quicker following initiation of radiation therapy ([**Figure 1A**](#pone-0012402-g001){ref-type="fig"}). Carriers of five or more unfavorable genotypes had a median time to event of only 1.1 months compared to over 12 months for those with three or less unfavorable genotypes (*P*\<0.0001).

![Event-free survival by number of unfavorable genotypes in inflammation-related genes.\
Kaplan-Meier curves of freedom from (**A**) grade \>2 esophagitis or (**B**) grade \>2 pneumonitis following radiation therapy. Numbers in parentheses are the number of patients with toxicity over the total number of patients; time is median event-free duration in months.](pone.0012402.g001){#pone-0012402-g001}
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###### Cumulative effect of unfavorable genotypes and radiation-induced toxicity risk.

![](pone.0012402.t003){#pone-0012402-t003-3}

  Number of Unfavorable Genotypes                      Grade \<2 n   Grade ≥2 n   [\*](#nt102){ref-type="table-fn"}HR         95% CI          *P* value
  --------------------------------------------------- ------------- ------------ ------------------------------------- -------------------- --------------
  **^\#^Esophagitis**                                                                                                                       
  0∼3                                                      49            11                      1.00                                       
  4                                                        23            14                    **3.71**                  **1.53 to 8.99**     **0.004**
  ≥5                                                       16            42                    **8.85**                 **4.19 to 18.68**    **\<0.0001**
  *P* trend                                                                                                                                  **\<0.0001**
  [&](#nt107){ref-type="table-fn"} **Phenumonitis**                                                                                         
  0∼2                                                      41            1                       1.00                                       
  3                                                        58            17                    **13.30**                **1.72 to 102.94**    **0.013**
  ≥4                                                       15            20                    **69.42**                **8.62 to 558.91**   **\<0.0001**
  *P* trend                                                                                                                                  **\<0.0001**

\*adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen,

radiation type, and radiation dosage**.**

^\#^unfavorable genotypes: IL6:rs1800795, IL16:rs11556218, TNF:rs1799724, PTGS2:rs20417.

PTGS2:rs5275, PTGS2:rs689470, IL4R:rs1801275, IL10:rs1800872, IL10RA:rs3135932.

IL1B:rs16944, IL2RB:rs228942, IL8:rs4073, IL10RB:rs2834167, IL13:rs1800925, NOS2:rs2297518.

unfavorable genotypes: IL1A:rs1800587, IL8:rs4073, TNF:rs1799724, TNFRSF1B:rs1061622.

MIF:rs7555622, IL4:rs2243250, IL4R:rs2070874, IL13:rs10800925, IL13:rs20541, NOS3:rs1799983, NFKBIA:rs1799983.

Inflammation-related SNPs and Risk of Pneumonitis {#s2c}
-------------------------------------------------

A different set of inflammation-related SNPs was found to be significantly associated with risk of developing pneumonitis following radiation therapy and remained so at an FDR of 10% ([**Table 4**](#pone-0012402-t004){ref-type="table"}). Only one of the 12 SNPs identified were also associated with esophagitis risk -- TNF:rs1799724. Patients homozygous for this variant exhibited a 5.96-fold increased risk (95% CI:1.33--18.57) of pneumonitis. This risk is similar for esophagitis risk in patients carrying at least one variant allele ([**Table 2**](#pone-0012402-t002){ref-type="table"}).

10.1371/journal.pone.0012402.t004

###### Inflammation-related SNPs and risk of pneumonitis.

![](pone.0012402.t004){#pone-0012402-t004-4}

                                                                         Grade \<2 n(%)   Grade ≥2 n(%)   [\*](#nt109){ref-type="table-fn"}HR        95% CI         *P* value    Q value                             Grade \<2 n(%)   Grade ≥2 n(%)   [\*](#nt109){ref-type="table-fn"}HR        95% CI         *P* value    Q value
  --------------------------------------------------------------------- ---------------- --------------- ------------------------------------- ------------------- ----------- ----------- ------------------------ ---------------- --------------- ------------------------------------- ------------------- ----------- -----------
  ***Proinflammatory cytokines, receptors, and related molecules***                                                                                                                                                                                                                                                        
  **IL1A:rs1800587**                                                          128              43                                                                                           **TNFRSF1B:rs1061622**        126              42                                                                              
  CC                                                                        65(50.8)        11(25.6)                     1.00                                                                         TT                72(57.1)        17(40.5)                     1.00                                                  
  CT                                                                      **51(39.8)**    **30(69.8)**                 **3.66**                 **1.66 to 8.07**    **0.001**                         TG                50(39.7)        22(52.4)                     1.84                     0.90 to 3.79        0.096    
  TT                                                                        12(9.4)          2(4.7)                      0.89                     0.19 to 4.23        0.885                           GG               **4(3.2)**      **3(7.1)**                  **5.88**                 **1.50 to 23.09**   **0.011**  
  CT+TT                                                                      **63**          **32**                    **2.90**                 **1.34 to 6.25**    **0.007**   **0.021**       *P* for trend                                                      **2.12**                 **1.18 to 3.79**    **0.012**   **0.023**
  **IL1A:rs17561**                                                            128              43                                                                                              **MIF:rs755622**           126              43                                                                              
  GG                                                                        65(50.8)        12(27.9)                     1.00                                                                         CC                89(70.6)        26(60.5)                     1.00                                                  
  GT                                                                      **52(40.6)**    **29(67.4)**                 **3.11**                 **1.44 to 6.72**    **0.004**                         CG                32(25.4)        12(27.9)                     1.49                     0.69 to 3.24        0.312    
  TT                                                                        11(8.6)          2(4.7)                      0.85                     0.18 to 4.01        0.836                           GG               **5(4.0)**      **5(11.6)**                 **4.49**                 **1.14 to 17.66**   **0.031**  
  GT+TT                                                                      **63**          **31**                    **2.51**                 **1.19 to 5.27**    **0.015**   **0.024**        CC+CG vs. GG           **121**          **38**                    **3.96**                 **1.04 to 15.12**   **0.044**   **0.038**
  **IL8:rs4073**                                                              128              41                                                                                             **NOS3:rs1799983**          129              42                                                                              
  TT                                                                        37(28.9)         7(17.1)                     1.00                                                                         GG                51(39.5)        22(52.4)                     1.00                                                  
  TA                                                                        66(51.6)        19(46.3)                     1.35                     0.51 to 3.56        0.548                           GT                61(47.3)        17(40.5)                     0.53                     0.27 to 1.04        0.067    
  AA                                                                      **25(19.5)**    **15(36.6)**                 **3.88**                 **1.42 to 10.62**   **0.008**                         TT                17(13.2)         3(7.1)                      0.34                     0.08 to 1.51        0.157    
  TT+TA vs. AA                                                              **103**          **26**                    **3.16**                 **1.54 to 6.48**    **0.002**   **0.010**       *P* for trend                                                      **0.55**                 **0.31 to 0.96**    **0.037**   **0.038**
  **TNF:rs1799724**                                                           121              42                                                                                                                                                                                                                          
  CC                                                                        94(77.7)        30(71.4)                     1.00                                                                                                                                                                                              
  CT                                                                        23(19.0)         9(21.4)                     1.45                     0.64 to 3.26        0.370                                                                                                                                                
  TT                                                                       **4(3.3)**      **3(7.1)**                  **5.32**                 **1.40 to 20.22**   **0.014**                                                                                                                                              
  CC+CT vs. TT                                                              **117**          **39**                    **4.96**                 **1.33 to 18.57**   **0.017**   **0.024**                                                                                                                                  
  ***Anti-inflammatory cytokines, receptors, and related molecules***                                                                                                                                                                                                                                                      
  **IL4:rs2243250**                                                           128              42                                                                                              **IL13:rs20541**           129              43                                                                              
  CC                                                                       103(80.5)        27(64.3)                     1.00                                                                         CC                88(68.2)        28(65.1)                     1.00                                                  
  CT                                                                      **22(17.2)**    **13(31.0)**                 **2.50**                 **1.22 to 5.11**    **0.012**                         CT                35(27.1)         9(20.9)                     0.98                     0.43 to 2.25        0.968    
  TT                                                                         3(2.3)          2(4.8)                      3.10                     0.34 to 28.02       0.313                           TT               **6(4.7)**      **6(14.0)**                 **2.94**                 **1.12 to 7.73**    **0.028**  
  CT+TT                                                                      **25**          **15**                    **2.54**                 **1.27 to 5.08**    **0.008**   **0.021**        CC+CT vs. TT           **123**          **37**                    **2.95**                 **1.14 to 7.63**    **0.025**   **0.031**
  **IL4:rs2070874**                                                           128              43                                                                                             **IL13:rs180925**           129              43                                                                              
  CC                                                                       104(81.3)        27(62.8)                     1.00                                                                         CC                83(64.3)        26(60.5)                     1.00                                                  
  CT                                                                      **21(16.4)**    **15(34.9)**                 **3.09**                 **1.49 to 6.44**    **0.003**                         CT                42(32.6)        13(30.2)                     0.71                     0.33 to 1.52        0.380    
  TT                                                                         3(2.3)          1(2.3)                      2.59                     0.27 to 24.47       0.405                           TT                 4(3.1)          4(9.3)                      2.97                     0.93 to 9.45        0.066    
  CT+TT                                                                      **24**          **16**                    **3.05**                 **1.50 to 6.22**    **0.002**   **0.010**        CC+CT vs. TT           **125**          **39**                    **3.23**                 **1.03 to 10.18**   **0.045**   **0.038**
  **NFKBIA:rs8904**                                                           127              43                                                                                                                                                                                                                          
  CC                                                                        54(42.5)        12(27.9)                     1.00                                                                                                                                                                                              
  CT                                                                        53(41.7)        16(37.2)                     0.99                     0.42 to 2.30        0.974                                                                                                                                                
  TT                                                                        20(15.7)        15(34.9)                     2.00                     0.84 to 4.79        0.119                                                                                                                                                
  CC+CT vs. TT                                                              **107**          **28**                    **2.02**                 **1.01 to 4.03**    **0.047**                                                                                                                                              

\*adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen, radiation type, and radiation dosage.

### Proinflammatory Genes {#s2c1}

Other significant genetic variants associated with pneumonitis included six SNPs in proinflammatory genes, including *IL1A*, *IL8*, *TNFRSF1B, MIF*, and *NOS3*. Two SNPs in *IL1A* -- rs1800587 and rs17561-- are in strong linkage disequilibrium and each resulted in a more than doubling of risk with HRs of 2.90 (95% CI:1.34--6.25) and 2.51 (95% CI:1.19--5.27), respectively. The risk associated with IL8:rs4073 was similar at 3.16-fold (95% CI:1.54--6.48). Under the additive model, TNFRSF1B:rs1061622 resulted in a 2.12-fold increased risk (95% CI:1.18--3.79). A SNP in the lymphokine gene *MIF* resulted in an even higher HR of 3.96 (95% CI:1.04--15.12). In contrast, genetic variation in *NOS3* was associated with a 50% decrease in pneumonitis risk (HR:0.55, 95% CI:0.31--0.96). This was the only SNP in our analysis to be significantly associated with a reduction in risk.

### Anti-inflammatory Genes {#s2c2}

IL4 and IL13 share a common receptor and have many of the same anti-inflammatory functions. In our population, we found that genetic variations in both of these interleukins were associated with increased risks of developing pneumonitis. The two *IL4* SNPs each resulted in increased risk with HRs of 2.54 (95% CI:1.27--5.08) and 3.05 (95% CI:1.50--6.22), respectively. *IL13* polymorphisms had a similar effect on pneumonitis risk. Patients with two variant alleles or either rs20541 or rs180925 were approximately 3-times more likely to develop pneumonitis compared to those with wild-type or heterozygous genotypes (HR:2.95, 95% CI:1.14--7.63 and HR:3.23, 95% CI:1.03--10.18). The signaling molecule IkappaB-alpha (*NFKBIA*) inhibits the inflammatory response by blocking NFkappaB-mediated transcription of proinflammatory genes. NFKBIA:rs8904 resulted in a 2.02-fold increased pneumonitis risk (95% CI:1.01--4.03).

### Joint Analysis of Pneumonitis Risk Alleles {#s2c3}

In combined analysis, the significant SNPs together with an additional borderline significant variant -- IL4R: rs1801275 (*P* = 0.053) -- showed an increase in pneumonitis risk as the number of unfavorable genotypes increased ([**Table 3**](#pone-0012402-t003){ref-type="table"}). The increased risk for carrying three unfavorable genotypes was 13.30-fold compared to patients with 0 to 2 risk genotypes (*P* = 0.013). This risk was dramatically increased for the group of patients with four or more unfavorable genotypes (*P*\<0.0001). These high risk individuals also had a shorter duration between start of treatment and development of pneumonitis of only 5.33 months compared to over 12 months for those with 0 to 2 unfavorable genotypes ([**Figure 1B**](#pone-0012402-g001){ref-type="fig"}).

Inflammation-related SNPs and Overall Survival {#s2d}
----------------------------------------------

The development of toxicity and survival are often related since patients who develop toxicity are those who are responding to treatment. Therefore, we determined if any of the variants identified as toxicity risk factors were also associated with survival over three years. We found that patients with at least one variant allele of IL10:rs1800872 had a 1.74-fold increased risk of esophagitis, but a 40% decreased risk of dying when compared to patients with wild-type genotypes (HR:0.62, 95% CI:0.40--0.97). [**Figure 2A**](#pone-0012402-g002){ref-type="fig"} illustrates the time to esophagitis for patients with IL10:rs1800872 genotypes. Although not significant, patients with wild-type genotypes had median time to event of greater than 12 months contrasted with only 1.8 months for those with at least one variant of rs1800872. For survival ([**Figure 2B**](#pone-0012402-g002){ref-type="fig"}), there was a non-significant survival advantage of nearly four months for carriers with a median survival time of 16.1 months compared to only 12.4 months for patients with wild-type genotypes.

![Relationship between esophagitis and overall survival.\
(**A**) Kaplan-Meier curves of freedom from grade \>2 esophagitis following radiation therapy by IL10:rs1800872 genotypes. Numbers in parentheses are the number of patients with toxicity over the total number of patients; time is median event-free duration in months. (**B**) Kaplan-Meier curves of overall survival following radiation therapy by IL10:rs1800872 genotypes. Numbers in parentheses are the number of patients alive over the total number of patients; time is median survival time in months.](pone.0012402.g002){#pone-0012402-g002}

Discussion {#s3}
==========

In this study, we systematically analyzed 59 common genetic variations in inflammation-related genes for association with risk of developing acute esophagitis or pneumonitis following radiation treatment in NSCLC patients. Multiple individual SNPs in important pro- and anti-inflammatory genes were identified as modulating risk for both normal tissue toxicities. Furthermore, the cumulative effect of these SNPs was dose-dependent with individuals carrying multiple unfavorable alleles having a corresponding increase in risk.

Nine genetic variants were identified as significantly associated with esophagitis risk, and of those, six were in proinflammatory genes ([**Table 2**](#pone-0012402-t002){ref-type="table"}). We found that rs1800795 in *IL6* resulted in a 2.16-fold increase in esophagitis. This polymorphism is located within the 5′-untranslated region of *IL6* and has been functionally studied with conflicting results of the effect on gene expression and response to stimulation [@pone.0012402-Kiszel1], [@pone.0012402-Terry1]. However, a recent meta-analysis of over 5,500 patients was not able to demonstrate a relationship between this variant and IL6 serum levels [@pone.0012402-Huth1]. Gao et al. demonstrated that IL16:rs11556218 was significantly associated with colorectal and gastric cancer, but did not observe a correlation between IL16 serum levels measured in these patients and rs11556218 [@pone.0012402-Gao1]. PTGS2:rs20417 was also associated with increased risk of esophagitis. This promoter variant disrupts a Sp1/Sp3 transcription factor binding site and causes a decrease in transcriptional activity in lung fibroblast cells [@pone.0012402-Hill1], [@pone.0012402-Papafili1]. Decreased expression of COX2 would suggest a decrease in inflammation signaling. However, this same variant, while altering the Sp1/Sp3 site, also introduces a binding site for another transcription factor, Egr-1, although the consequences are unknown [@pone.0012402-Hill1]. The other two significant variants (rs5275 and rs689470) are located in the 3′-UTR and regulate *PSTGS2* mRNA levels. Our results suggest that these SNPs are linked with an increase in pro-inflammatory activity leading to esophagitis. Further functional analysis is warranted to understand the underlying mechanisms [@pone.0012402-Dixon1].

For anti-inflammatory molecules and esophagitis risk, Khurana Hershey et al. demonstrated that IL4R:rs1801275 resulted in enhanced IL4 signaling and the induction of high levels of the IgE receptor CD23 [@pone.0012402-Hershey1]. IL10:rs1800872 and IL10RA:rs3135932 have been shown to decrease IL10 signaling by decreasing serum levels and altering IL10-IL10RA interactions, respectively [@pone.0012402-Crawley1], [@pone.0012402-Gasche1]. The reported functions of these three SNPs would be in agreement with our findings of an increased risk of esophagitis by decreasing the anti-inflammatory response.

Twelve common polymorphisms were found to be significantly associated with risk of pneumonitis. The two *IL1A* variants are in linkage disequilibrium and were found to increase risk by nearly 3-fold. IL1A:rs1800587 has been shown to contribute to an increase in IL1-α promoter activity, mRNA levels and protein levels [@pone.0012402-Dominici1]. IL1A:rs17561 is a non-synonymous SNP and increases processing of the IL1-α precursor resulting in an increase in the levels of active IL1-α [@pone.0012402-Kawaguchi1]. The variant of IL8:rs4073, which was found to increase pneumonitis risk 3-fold, has been associated with increased secretion of the proinflammatory cytokine IL8 [@pone.0012402-Hull1]. IL4 and IL13 work together to regulate the inflammatory response. Four genetic variants in these two genes were associated with ∼3-fold increased risk of pneumonitis. Studies have demonstrated increased IgE production for IL4:rs2070874 and rs2243250 [@pone.0012402-Kabesch1] and increased IL13 activity for IL13:rs20541 and rs180925 [@pone.0012402-Vladich1], [@pone.0012402-Cameron1].

Genetic variation in *TNF* and the receptor *TNFRSF1B* were also associated with increased risk of pneumonitis. TNF-α signaling is an important modulator of the inflammatory response. The TNF:rs1799724 variant is located within the promoter region of the gene and thought to influence gene expression by creating an OCT-1 transcription factor binding site [@pone.0012402-Hohjoh1]. The effect of this differential binding on TNF-α signaling is not clear. Some studies have shown an increase in TNF-α production [@pone.0012402-Higuchi1], [@pone.0012402-Lv1], [@pone.0012402-Soga1], while others have shown the opposite effect [@pone.0012402-Puthothu1], [@pone.0012402-Sato1], [@pone.0012402-vanHeel1]. For TNFRSF1B, the non-synonymous variant Met196Arg (rs1061622) does not alter TNF-α binding affinity, but results in intensified TNF-α signaling [@pone.0012402-Morita1] and decreased NF-kB signaling [@pone.0012402-Till1].

Only one genetic variant was found to confer a protective effect following radiotherapy. This variant, rs1799983, in *NOS3* was associated with a 70% reduction in risk of pneumonitis. Functional studies have demonstrated that this variant results in production of a variant allozyme with reduced enzyme activity [@pone.0012402-Wang2] resulting in a reduction in nitric oxide production [@pone.0012402-Veldman1]. These observations support our findings of decreased pneumonitis due to decreased inflammatory signaling.

In all, the functional consequences of the variants identified as strongly associated with increased risk of normal tissue toxicity following radiation exposure suggest a high biological plausibility for our findings. However, little to no information is known about how these variants specifically alter pneumonitis and esophagitis risk. The inflammatory response is complex and many prototypic "proinflammatory" molecules have anti-inflammatory attributes under specific conditions, and vice versa. Further studies are warranted to elucidate the specific function of these SNPs in target tissues following exposure to radiation.

Interestingly, we observed several variants with a trend towards a relationship between toxicity and overall survival, and only one SNP was identified as being associated with both. This result suggests that these patients who are developing acute normal tissue toxicity are responding well to therapy with longer survival times. Unfortunately, these side effects are dose limiting and often result in cessation of treatment. It may be that these select patients would receive the most benefit from the inclusion of radioprotective agents such as amifostine and glutamine in their treatment regimen. Both work by decreasing the levels of reactive oxygen species in the exposed normal tissue and, thus, potentially avoiding the development of inflammation. It would be of interest to test the significant SNPs identified in this study within the framework of these agents.

Our study has several advantages, including the patient population with availability of comprehensive clinical and epidemiological information. To our knowledge, no study has systematically investigated the effect of genetic variations within inflammation-related genes and risk of normal tissue toxicity due to radiation therapy. This pathway-based approach allowed us to comprehensively elucidate the cumulative effects of multiple adverse alleles on toxicity risk. Since a patient\'s genome can contain several of these risk associated genetic variants in both proinflammatory and anti-inflammatory pathways, this approach is much more powerful in detecting the effect of these SNPs on a patient\'s risk of developing esophagitis or pneumonitis. The variants included in this study were candidate SNPs based on known or predicted effects on gene function. A candidate-gene approach has the advantage of being anchored by known biological plausibility, but there is a possibility that this study has missed additional risk alleles or detected a variant in linkage disequilibrium with the true causative SNP. In addition, we were not able to include additional variables that may also impact toxicity, including radiation field size, dose to organ at risk (esophagus and lung), treatment volume, and tumor location.

In conclusion, we identified several biologically plausible associations between genetic variants in important inflammation-related genes and risk of developing esophagitis and pneumonitis. We also demonstrated a dose-effect of inflammation SNPs as evidenced by the dramatic increases in risk with increases in number of unfavorable genotypes. Furthermore, we identified one variant in IL10 that is associated with increased risk of esophagitis, but a decreased risk of dying. Since radiotherapy is a mainstay of lung cancer treatment, having the ability to screen patients prior to initiation of treatment would potentially minimize these acute toxicity events while allowing for higher doses of radiation for those who are not at increased risk in order to improve local control. With validation, these results, together with clinical and dosimetric predictors, could serve to increase the overall benefit of radiation therapy in NSCLC patients.

Methods {#s4}
=======

Ethics Statement {#s4a}
----------------

Participants gave written informed consent and the study was approved by The University of Texas MD Anderson Cancer Center\'s Institutional Review Board.

Patient Population {#s4b}
------------------

The study included non-Hispanic Caucasian subjects who were newly diagnosed, histologically confirmed stage IIIA or IIIB without a malignant effusion (dry) NSCLC patients receiving definitive thoracic radiation or chemoradiation therapy at The University of Texas MD Anderson Cancer Center. All of the patients were enrolled in an ongoing epidemiology lung cancer study between 1995 and 2007.

Epidemiological and Clinical Data Collection {#s4c}
--------------------------------------------

Epidemiologic data were collected during an in-person interview using a structured questionnaire to determine demographic characteristics, medical history, and smoking history. Clinical and follow-up information was abstracted from medical records. Pre-treatment performance status was determined based on the Eastern Cooperative Oncology Group scale. Radiation-induced esophagitis was characterized by documentation of new-onset pain on swallowing occurring during treatment. Pneumonitis was detected by roentgenographic or CT scan abnormalities and often associated with nonproductive cough and/or fever. Severity of pneumonitis or esophagitis was scored by the physician according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) guidelines [@pone.0012402-Trotti1]. For this study, an event was considered the occurrence of grade ≥2 toxicity.

SNP Selection and Genotyping {#s4d}
----------------------------

Blood was drawn from each participant following the in-person interview. These samples were used to extract genomic DNA from peripheral blood lymphocytes using the Human Whole Blood Genomic DNA Extraction Kit (Qiagen, Valencia, CA). A total of 59 candidate SNPs ([**Table 5**](#pone-0012402-t005){ref-type="table"}) were selected from 37 known inflammation-related genes as previously described [@pone.0012402-Engels1]. Briefly, candidate SNPs were selected if they had a minor allele frequency greater than 5% and were located in a putative functional region of the gene (promoter, untranslated regions (UTR) or exons) or had previously been reported as associated with cancer or an inflammatory disorder. Genotyping was performed using the SNPlex assay following manufacturer\'s instructions (Applied Biosystems, Foster City, CA) with analysis on an Applied Biosystems 3730 DNA Analyzer. SNP genotypes were called using the GeneMapper software (Applied Biosystems). Three SNPs: IL8RA:rs2234671, LTA:rs2229092 and IL4R:rs1805011 were removed because of excessive missing genotypes (\>20%). All genotyping was completed blinded with regard to toxicity status.

10.1371/journal.pone.0012402.t005

###### Inflammation single nucleotide polymorphism characteristics.

![](pone.0012402.t005){#pone-0012402-t005-5}

  dbSNP ID      Alleles   Gene Symbol                         Gene Name                         SNP Location[\*](#nt110){ref-type="table-fn"}
  ------------ --------- ------------- ------------------------------------------------------- -----------------------------------------------
  rs1800872       C/A        IL10                          interleukin 10                                          5\'-FR
  rs1800896       G/A        IL10                          interleukin 10                                          5\'-FR
  rs1900871       A/C        IL10                          interleukin 10                                          5\'-FR
  rs3135932       A/G       IL10RA                 interleukin 10 receptor, alpha                                 Ser159Gly
  rs2834167       A/G       IL10RB                  interleukin 10 receptor, beta                                 Lys47Glu
  rs1800925       C/T        IL13                          interleukin 13                                          5\'-FR
  rs20541         C/T        IL13                          interleukin 13                                         Arg130Gln
  rs2070874       C/T         IL4                           interleukin 4                                          5\'-UTR
  rs2243250       C/T         IL4                           interleukin 4                                          5\'-FR
  rs1801275       A/G        IL4R                      interleukin 4 receptor                                     Gln576Arg
  rs1805010       A/G        IL4R                      interleukin 4 receptor                                     Ile75Val
  rs1805011       A/C        IL4R                      interleukin 4 receptor                                     Glu400Ala
  rs1805015       T/C        IL4R                      interleukin 4 receptor                                     Ser503Pro
  rs1805016       T/G        IL4R                      interleukin 4 receptor                                     Ser752Ala
  rs2069812       C/T         IL5                      interleukin 5 receptor                                      5\'-FR
  rs2233409       C/T       NFKBIA                            IkB alpha                                            5\'-FR
  rs8904          C/T       NFKBIA                            IkB alpha                                            3\'-UTR
  rs1800206       C/G        PPARA        peroxisome proliferator-activated receptor alpha                        Leu162Val
  rs2016520       A/G        PPARD        peroxisome proliferator-activated receptor delta                         5\'-UTR
  rs1801282       C/G        PPARG        peroxisome proliferator-activated receptor gamma                        Pro12Ala
  rs1024611       T/C        CCL2                  chemokine (C-C motif) ligand 2                                  5\'-FR
  rs2069614       C/T        CSF2       colony stimulating factor 2 (granulocyte-macrophage)                       5\'-FR
  rs25882         T/C        CSF2       colony stimulating factor 2 (granulocyte-macrophage)                      Ile117Thr
  rs2257167       G/C       IFNAR1          interferon (alpha, beta and omega) receptor 1                         Val168Leu
  rs1051393       T/G       IFNAR2          interferon (alpha, beta and omega) receptor 2                         Phe10Val
  rs2069705       T/C        IFNG                         interferon, gamma                                        5\'-FR
  rs2430561       A/T        IFNG                         interferon, gamma                                        intron
  rs3212227       A/C        IL12B                         interleukin 12B                                         3\'-UTR
  rs375947        A/G       IL12RB                 interleukin 12 receptor, beta 1                                Met365Thr
  rs11556218      T/G        IL16                          interleukin 16                                         Asn446Lys
  rs4778889       T/C        IL16                          interleukin 16                                          5\'-FR
  rs17561         G/T        IL1A                       interleukin 1, alpha                                      Ala114Ser
  rs1800587       C/T        IL1A                       interleukin 1, alpha                                       5\'-FR
  rs1143627       T/C        IL1B                        interleukin 1, beta                                       5\'-FR
  rs1143634       C/T        IL1B                        interleukin 1, beta                                      Phe105Phe
  rs16944         C/T        IL1B                        interleukin 1, beta                                       5\'-FR
  rs2228139       C/G        IL1R1                 interleukin 1 receptor, type I                                 Ala124Gly
  rs2069762       T/G         IL2                           interleukin 2                                          5\'-FR
  rs228942        C/A        IL2RB                  interleukin 2 receptor, beta                                  Asp391Glu
  rs1800795       C/G         IL6                interleukin 6 (interferon, beta 2)                                5\'-FR
  rs2228145       A/C        IL6R                      interleukin 6 receptor                                     Asp358Ala
  rs4073          T/A         IL8                           interleukin 8                                          5\'-FR
  rs2234671       G/C        IL8RA                  interleukin 8 receptor, alpha                                 Ser276Thr
  rs2229092       A/C         LTA                         lymphotoxin alpha                                       His51Pro
  rs2229094       T/C         LTA                         lymphotoxin alpha                                       Arg13Cys
  rs755622        C/G         MIF              macrophage migration inhibitory factor                              5\'-FR
  rs1799724       C/T         TNF                       tumor necrosis factor                                      5\'-FR
  rs1799964       T/C         TNF                       tumor necrosis factor                                      5\'-FR
  rs1800629       G/A         TNF                       tumor necrosis factor                                      5\'-FR
  rs361525        G/A         TNF                       tumor necrosis factor                                      5\'-FR
  rs4149570       G/T      TNFRSF1A     tumor necrosis factor receptor superfamily, member 1A                      5\'-FR
  rs4149584       G/A      TNFRSF1A     tumor necrosis factor receptor superfamily, member 1A                     Arg121Gln
  rs1061622       T/G      TNFRSF1B     tumor necrosis factor receptor superfamily, member 1B                     Met196Arg
  rs5746026       G/A      TNFRSF1B     tumor necrosis factor receptor superfamily, member 1B                     Glu232Lys
  rs2297518       G/A        NOS2                nitric oxide synthase 2, inducible                               Leu608Ser
  rs1799983       G/T        NOS3            nitric oxide synthase 3 (endothelial cell)                           Glu298Asp
  rs20417         G/C        PTGS2              prostaglandin-endoperoxide synthase 2                              5\'-FR
  rs5275          T/C        PTGS2              prostaglandin-endoperoxide synthase 2                              3\'-UTR
  rs689470        C/T        PTGS2              prostaglandin-endoperoxide synthase 2                              3\'-UTR

\*FR: flanking region, UTR: untranslated region.

Statistical Analysis {#s4e}
--------------------

Time to event (grade ≥2 pneumonitis or esophagitis) was based on the duration from start of radiation treatment to occurrence of toxicity. Three-year survival was also defined as the time from start of radiation treatment to the date of death or the date of last follow-up during the three year period. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for each individual SNP and endpoint combination were estimated by fitting the Cox proportional hazard model while adjusting for age, gender, clinical stage, pack years of smoking, pre-treatment performance status, treatment regimen (radiotherapy or chemoradiotherapy), radiation type, and radiation dosage. Kaplan-Meier curves and log-rank tests were used to assess differences in time to event and overall survival rates. Combined effects of unfavorable genotypes were based on the main effect analysis of individual SNPs and included those with significant (*P*\<0.05) and borderline significant (*P*\<0.10) associations. STATA software (version 10, STATA Corp., College Station, TX) was used for statistical analyses. Q-values were calculated to control for multiple comparisons based on an FDR value of 10% [@pone.0012402-Storey1].
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